December 2023 in “Journal of dermatology” Adults and adolescents with severe alopecia areata are willing to take significant health risks for a better chance of hair regrowth.
1 citations
,
June 2023 in “Dermatology and therapy” People with Alopecia Areata have more herpes simplex infections but similar rates of cancer, blood clots, and heart disease compared to those without it.
September 2025 in “International Journal of Molecular Sciences” Deucravacitinib may help treat various immune diseases beyond psoriasis, but more research is needed.
May 2025 in “Journal of the European Academy of Dermatology and Venereology” Etrasimod is safe but not effective for severe alopecia areata, though it may help milder cases.
JAK inhibitors effectively regrow hair in children with alopecia areata and are safe to use.
4 citations
,
March 2025 in “The Journal of Dermatology” Ritlecitinib is effective and safe for hair regrowth in Asian patients with alopecia areata.
13 citations
,
February 2025 in “Journal of the European Academy of Dermatology and Venereology” Ritlecitinib shows promise for treating alopecia areata, especially with early and extended treatment.
11 citations
,
September 2024 in “Journal of the European Academy of Dermatology and Venereology” Hair regrows faster in alopecia areata than skin re-pigments in vitiligo due to differences in stem cells and treatment effects.
7 citations
,
October 2024 in “Journal of the American Academy of Dermatology” Continued ritlecitinib treatment helps sustain hair regrowth in alopecia areata patients.
3 citations
,
February 2025 in “Journal of Dermatological Treatment” Hair regrowth in Alopecia Areata patients leads to increased satisfaction and reduced stress.
1 citations
,
January 2025 in “CPT Pharmacometrics & Systems Pharmacology” Ritlecitinib effectively regrows eyebrow and eyelash hair in alopecia areata, with 50 mg being the best dose.
April 2025 in “Frontiers in Immunology” Tofacitinib effectively regrows hair in alopecia areata but may need continuous use.
New drugs, baricitinib and ritlecitinib, are effective for severe alopecia areata.
15 citations
,
January 2025 in “Journal of the European Academy of Dermatology and Venereology” Ritlecitinib is effective and safe for treating alopecia areata, promoting significant hair regrowth.
January 2023 in “IntechOpen eBooks” The document concludes that specific methods for making diazine-based drugs can lead to high yields and are important for creating effective treatments for various diseases.
February 2026 in “Biomedicines” Off-label treatments are heavily used for alopecia areata due to limited approved options.
June 2025 in “bioRxiv (Cold Spring Harbor Laboratory)” In alopecia areata, certain immune cells increase and express a protein linked to immune activation.
January 2025 in “Advances in Clinical Medicine” Injection therapies show promise as effective treatments for hair loss.
April 2026 in “International Journal of Molecular Sciences” Targeting non-Smad pathways in TGF-β signaling may improve keloid treatment.
May 2025 in “Acta Dermato Venereologica” Alopecia areata patients have higher risks of infections, lymphoma, heart issues, and death.
January 2025 in “Journal of Cutaneous Immunology and Allergy” Baricitinib is effective for treating severe alopecia areata in Japanese patients, but long-term safety needs more study.
90 citations
,
February 2001 in “The journal of investigative dermatology/Journal of investigative dermatology” Interleukin-1 increases keratin K6 production in skin cells.
21 citations
,
April 2025 in “MedComm” Alopecia areata causes unpredictable hair loss, and more research is needed to fully understand and treat it effectively.
2 citations
,
September 2024 in “Journal of the American Academy of Dermatology” Deuruxolitinib significantly helps regrow scalp hair in adults with moderate to severe alopecia areata.
1 citations
,
November 2025 in “Journal of Dermatological Treatment” Baricitinib is effective and safe for treating severe alopecia areata.
March 2026 in “Frontiers in Pediatrics” COVID-19 may trigger hair loss conditions like alopecia areata.
January 2026 in “Lab on a Chip” Organoids and hair-on-chip technologies show promise for hair regeneration but face clinical challenges.
November 2025 in “Biomedicines” Targeting pyroptosis may offer new treatments for alopecia areata, but more research is needed.
October 2025 in “Journal of Advanced Trends in Medical Research” Rosemary shows promise in treating alopecia, similar to minoxidil, but more research is needed.
July 2024 in “Journal of Investigative Dermatology” Losing both ERBB2 and ERBB3 receptors in mice causes significant skin problems and inflammation.